On November 9, 2020 Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, reported that pre-clinical research results focusing on its PD1-41BB switch receptor technology in a poster to be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 35th Annual Meeting (SITC 2020) being held virtually on 9-14 November 2020 (Press release, MediGene, NOV 9, 2020, View Source [SID1234570395]). The poster # 614 will be available in the Virtual Poster Hall from 11-14 November 2020 from 9:00 am – 5:00 pm EST (3:00 pm – 11:00 pm CET), Q&A sessions will be held on Thursday, 12 November 2020, 4:50 pm – 5:20 pm EST (10:50 pm – 11:20 pm CET) and on Saturday, 14 November 2020, 1:00 pm – 1:30 pm EST (7:00 pm – 7:30 pm CET).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster # 614 entitled, "Co-stimulation via PD1-41BB chimeric switch receptor enhances function of TCR-T cells in an immune-suppressive milieu and under chronic antigen stimulation", describes 2- and 3-dimensional in vitro tumor cell culture models representing the harsh conditions encountered by T cells in solid tumors including low nutrients and high levels of immunosuppressive soluble factors. T cell receptor-modified T cells (TCR-Ts) which also express Medigene’s PD1-41BB switch receptor have the ability to overcome the inhibitory tumor microenvironment and repeatedly kill tumor cells in multiple challenges. The PD1-41BB expressing TCR-T cells show a higher level of metabolic fitness enabling them to persist and proliferate much more effectively despite the normally negative factors produced by tumor cells.
Further research including in vivo studies and safety evaluations will be conducted towards eventual clinical trials of PD1-41BB-expressing TCR-T cells in the therapeutic treatment of solid tumors.
Prof. Dolores Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene: "In preclinical studies we have shown that our PD1-41BB switch receptor significantly enhances the functionality of TCR-Ts in a hostile solid tumor microenvironment. Enabling our TCR-Ts to function with greater activity in the solid tumor setting, which normally shuts T cells down, should give our TCR-Ts the ability to persist longer and hopefully bring about durable therapeutic responses in the clinic."
The poster will be available at www.medigene.com/technologies/abstracts from 11 November 2020, 9:00 am EST (3:00 pm CET).